A new study has revealed that patients with benign prostatic hyperplasia (BPH) carrying prostate cancer a (PCa) risk alleles are a potential target population for PCa screening and follow-up. The study was presented yesterday at the 28th Annual EAU Congress in Milan. The study aimed to evaluate the genetic predisposition of patients with BPH to developing prostate cancer, with findings suggesting that genetic testing may offer a new tool to identify BPH patients ...
View the original article here
This post was made using the Auto Blogging Software from WebMagnates.org This line will not appear when posts are made after activating the software to full version.
Extensive research has shown that hormonal therapies can help control advanced prostate cancer for a time. However, for most men, at some point their prostate cancer eventually stops responding to further hormonal treatment. This stage of the disease is called androgen-insensitive or castration-resistant prostate cancer. In a study published March 18 in iCancer Cell/i, a team led by researchers at Sanford-Burnham Medical Research Institute (Sanford-Burnham) ...
A new study conducted by Japanese researchers has found that combining multi-peptide vaccination therapy with the low-dose steroid drug dexamethasone can be effective in treating chemotherapy-naive castration resistant prostate cancer (CRPC) patients. The study, which won the third prize for best abstract in oncology at the 28th European Association of Urology Congress held in Milan, Italy from 15 to 19 March, showed the promising benefit of this combination therapy ...
